Hikma Pharmaceuticals Plc Hikma and Richter sign agreement for cariprazine
25 Luglio 2019 - 8:02AM
RNS Non-Regulatory
TIDMHIK
Hikma Pharmaceuticals Plc
25 July 2019
London, 25 July 2019 - Hikma Pharmaceuticals PLC (Hikma, Group)
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's /
BB+ S&P, both stable), the multinational pharmaceutical
company, and Gedeon Richter PLC (Richter) today announced the
signing of an exclusive license agreement to commercialise
cariprazine, a novel antipsychotic, in certain Middle East and
North African (MENA) markets.
Under the terms of the agreement, Richter will be responsible
for product supply and Hikma will proceed with the registration and
commercialisation of the product in the following markets: Bahrain,
Egypt, Jordan, Iraq, Saudi Arabia, Kuwait, Lebanon, Libya, Morocco,
Oman, Qatar, Sudan, Syria and United Arab Emirates. According to
IQVIA, sales for atypical antipsychotics in these markets were $153
million for the 12 months ending March 2019. Richter will receive
from Hikma an upfront payment. In addition, Richter will be
entitled to sales related milestone payments on achievement of
certain targets.
Mazen Darwazah, Hikma's Executive Vice Chairman and President of
MENA said, "We are very pleased to form a partnership with Richter,
adding a novel product to our portfolio in a key therapeutic area.
CNS disorders are becoming more prevalent across the MENA and this
partnership enables us to meet the needs of a growing number of
patients."
Mr Gábor Orbán, Chief Executive Officer of Richter said, "We
consider this recent partnership agreement as a further step to
achieve a global presence of cariprazine in the treatment of
patients suffering from schizophrenia".
About cariprazine
Cariprazine is an oral, once daily atypical antipsychotic
approved by the FDA for the acute treatment of manic or mixed
episodes associated with bipolar I disorder in adults, for the
treatment of depressive episodes associated with bipolar I disorder
(bipolar depression) in adults and for the treatment of
schizophrenia in adults. Apart from having been available on the US
market for more than three years cariprazine is also approved in
the EU for schizophrenia indication and has already been marketed
in 15 European countries.
Cariprazine was discovered by Gedeon Richter PLC and was
licensed out to Allergan in the United States. For more than a
decade both companies have co-developed the molecule by conducting
over 50 clinical trials enrolling thousands of patients worldwide
to evaluate the efficacy and safety of cariprazine for people
living with a broad range of mental health illnesses. While Gedeon
Richter PLC markets the molecule on its own in Central-Eastern
Europe, Western European marketing rights were licensed to
Recordati and other license agreements have been signed with
further strong local partners to ensure that cariprazine would be a
treatment option to many patients globally suffering from these
debilitating diseases.
-- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal +44 (0)20 7399 2760/ +44 7776
EVP, Strategic Planning and Global 477050
Affairs uk-investors@hikma.com
Gedeon Richter PLC
Katalin Ördög, Investors +36 1 431 5680
Zsuzsa Beke, Media +36 1 431 4888
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we're a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,400 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner in the MENA region, and through our
venture capital arm, are helping bring innovative health
technologies to people around the world. For more information,
please visit www.hikma.com.
About Richter
Gedeon Richter PLC (www.richter.hu), headquartered in Budapest /
Hungary, is a major pharmaceutical company in Central Eastern
Europe, with an expanding direct presence in Western Europe, China
and in Latin America. Having reached a market capitalisation of EUR
3.2 billion (USD 3.6 billion) by the end of 2018, Richter's
consolidated sales were approximately EUR 1.4 billion (USD 1.6
billion) during the same year. The product portfolio of Richter
covers many important therapeutic areas, including Women's
Healthcare, Central Nervous System and Cardiovascular areas. Having
the largest R&D unit in Central Eastern Europe, Richter's
original research activity focuses on CNS disorders. With its
widely acknowledged steroid chemistry expertise, Richter is a
significant player in the Women's Healthcare field worldwide.
Richter is also active in biosimilar product development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAPGURGMUPBPUC
(END) Dow Jones Newswires
July 25, 2019 02:02 ET (06:02 GMT)
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2023 a Apr 2024